Is the open mouth mightier than the needle?


In this issue of Blood, Bernard et al provide evidence that ibrutinib, the orally administered inhibitor of Bruton tyrosine kinase (BTK), crosses the blood-brain barrier and has activity against mantle cell lymphoma (MCL) in the central nervous system (CNS).

DOI: 10.1182/blood-2015-08-664060

Cite this paper

@article{Martin2015IsTO, title={Is the open mouth mightier than the needle?}, author={Peter Martin}, journal={Blood}, year={2015}, volume={126 14}, pages={1638-9} }